Economic Rules Hub
  • World
  • Politics
  • Business
  • Investing
Home Investing ISLA-101 Phase 2a/b PROTECT Clinical Trial Progress Update
Investing

ISLA-101 Phase 2a/b PROTECT Clinical Trial Progress Update

by admin November 18, 2024
November 18, 2024

Australian antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA; Island or the Company) is pleased to announce progress on its ISLA-101 Phase 2a/b clinical trial in dengue fever.

  • All key data samples have been collected following dosing of all subjects in the Phase 2a (prophylactic) trial as part of Island’s ISLA-101 Phase 2a/b PROTECT clinical trial in dengue fever
  • Data currently being consolidated for review by the Safety Review Committee (SRC) in the coming weeks
  • On track to release SRC recommendation on advancing the trial to Phase 2b by end of this calendar year
In Island’s Phase 2a trial, subjects receive ISLA-101 before being infected with a weakened dengue virus developed by the US Army. The trial aims to assess whether ISLA-101 can prevent or reduce viremia and symptoms compared to a placebo, based on previous control data showing elevated viremia and symptoms in untreated subjects.

Following the announcement (ASX: 3 October 2024) that all subjects in the Phase 2a cohort of the trial had been dosed, Island confirms it has now collected the required samples to analyse how the viremia (viral load) levels in the blood of trial subjects have changed through the study. Other samples are being analysed for pharmacokinetic data as well as other blood analyses.

This data is currently being consolidated for review by the Safety Review Committee (SRC), who will meet in the coming weeks. The SRC will evaluate the safety of ISLA-101 in dengue infected individuals and consider if there is evidence of anti-dengue activity. They will then make a recommendation regarding advancing the trial to the Phase 2b cohort before the end of the calendar year.

Island’s CEO and Managing Director, Dr David Foster commented, “We are very pleased to be able to report that 46 days into the trial, we’ve collected the key data required for evaluation by the Safety Review Committee. From here, while we will continue to check in with patients up to 90 days post dosing, we look forward to providing all the data to the SRC for evaluation in the coming weeks. Importantly, this means we remain on track to report data before the end of the year from our Phase 2a component, and next steps for the Phase 2b cohort before the end of the year.”

Phase 2b will include 10 subjects randomised 8:2 (active: placebo) and will examine if ISLA-101 has activity as a treatment against dengue infection. This is the first time a potential countermeasure to combat the dengue virus, which afflicts more than 400 million individuals a year and for which there is no therapeutic option, is being investigated as both a preventative and therapeutic measure.

To subscribe to Island’s monthly newsletter, IslandWatch, and other forms of email communications, please visit this page of our website.

Click here for the full ASX Release

This post appeared first on investingnews.com

0
FacebookTwitterPinterestEmail
previous post
Gunnison Releases PEA for Arizona Copper Project, Plans for Open-pit, Heap-leach Operation
next post
Radiopharm Theranostics CEO Shares Company Milestones as NASDAQ Listing Nears

Related Posts

Metals & Mining Virtual Investor Conference: Presentations Now Available for...

July 26, 2025

Homerun Resources Inc. Files for Approval of $3 Million Financing;...

July 26, 2025

Pinnacle Increases Non-Brokered Private Placement

July 26, 2025

Teck Greenlights Highland Valley Expansion After Beating Q2 Profit Estimates

July 26, 2025

Top 5 Canadian Mining Stocks This Week: St. Augustine Gains...

July 26, 2025

Editor’s Picks: Miners Rescued, US Mine Waste Strategy, Ontario Expands...

July 26, 2025

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent

    • Trump says SCOTUS immunity ruling likely helps Obama in light of Gabbard, DNI findings

      July 26, 2025
    • ‘Louder by the hour’: Senate GOP wants the Epstein drama to end, but Democrats aren’t letting it go

      July 26, 2025
    • Pentagon freezes out DC think tanks in new move, citing ‘America last’ concerns

      July 26, 2025
    • Pelosi confident about Dems’ chances to win House, predicts Jeffries will be speaker

      July 26, 2025
    • House Freedom Caucus conservative to enter race for South Carolina governor

      July 26, 2025

    Categories

    • Business (1,464)
    • Investing (3,757)
    • Politics (4,996)
    • World (4,720)
    • Email Whitelisting
    • Terms and Conditions
    • Privacy Policy
    • Contacts
    • About us

    Disclaimer: EconomicRulesHub.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 EconomicRulesHub.com | All Rights Reserved

    Economic Rules Hub
    • World
    • Politics
    • Business
    • Investing